PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
MWN-AI** Summary
On February 24, 2026, PacBio (NASDAQ: PACB) announced a landmark collaboration with DNAstack, launching the world’s first global federated dataset of HiFi whole genome sequencing data aimed at accelerating rare disease research. This initiative, backed by the HiFi Solves Global Consortium, facilitates secure international research, allowing genomic insights to transcend borders while safeguarding sensitive data within institutional control.
With nearly 30 clinical and research institutions from 15 countries involved, the consortium has connected over 10,000 HiFi whole genome sequences, creating one of the largest federated datasets for rare disease research. PacBio's HiFi sequencing technology, renowned for its accuracy and completeness, offers researchers the ability to confidently detect complex genetic variants, thereby enhancing variant interpretation and expediting discoveries for patients with rare diseases.
Christian Henry, President and CEO of PacBio, emphasized that this partnership enhances the potential of HiFi sequencing by allowing for robust collaborative analysis on a global scale while respecting local data governance. Marc Fiume, CEO of DNAstack, added that the federated model is critical for drawing insight from global datasets while ensuring participant privacy, thus accelerating rare disease diagnoses.
The HiFi Solves Global Consortium's federated approach significantly augments statistical power for rare disease studies, enabling insights that would be challenging to gather in isolated datasets. Eric Vilain, M.D., from UC Irvine, noted that this collaboration allows for secure variant filtering, ultimately leading to faster and more reliable answers for families waiting for diagnoses.
This innovative venture marks an essential step in merging advanced genomic technologies with collaborative research, promising greater understanding and solutions for rare genetic disorders.
MWN-AI** Analysis
The recent collaboration between PacBio (NASDAQ: PACB) and DNAstack, along with the formation of the HiFi Solves Global Consortium, marks a pivotal moment in the genomic research landscape, particularly in rare diseases. Investors should keenly observe this development as it signals a strategic escalation in both companies’ capabilities to harness genomic data while addressing privacy concerns.
PacBio’s HiFi whole genome sequencing technology is gaining recognition for its unprecedented accuracy and ability to resolve complex genetic variants. With over 30 institutions across 15 countries committed to contributing to this federated dataset, the potential for groundbreaking discoveries and enhanced understanding of rare diseases increases substantially. This collaborative model not only accelerates research timelines but also boosts statistical power that would be challenging to achieve using isolated datasets.
However, while the consortium represents significant upside opportunities for PacBio, it’s crucial to navigate potential risks. The integration of multiple data sources while ensuring compliance with varying privacy regulations is complex. Investors should closely monitor regulatory developments that may impact PacBio’s operations and the scalability of this model.
Moreover, as the competition in the genomic sequencing sector intensifies, PacBio's success will depend on how quickly it can translate collaborative insights into commercial viability. The company’s commitment to resolving the genetic underpinnings of rare diseases is promising, but execution in terms of technology adoption and partnership efficacy will determine future performance.
In conclusion, while PacBio appears well-positioned within a growing market for genomic technologies, investors should be vigilant of evolving challenges and opportunities in regulatory landscapes and technological advancements. Given the momentum from this consortium, expansions and updates should be closely monitored as they will likely influence stock performance, making PacBio a company to watch in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced a collaboration with DNAstack to power the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collaboration enables secure international research — allowing genomic insights to travel across borders while sensitive data remains under institutional control.
Participating institutions connect HiFi whole genome sequencing data and associated metadata within a highly secure federated environment. Hosted by DNAstack and accessible at https://hifisolves.org, the platform enables researchers to query harmonized datasets across institutions without centralizing protected data, supporting global collaboration while maintaining compliance with regional data privacy regulations.
The consortium now includes nearly 30 clinical and research institutions across 15 countries spanning North America, Europe, the Middle East, Africa, East Asia, and Southeast Asia, with continued expansion underway. Collectively, members have connected or committed to connect more than 10,000 HiFi whole genome sequences — forming one of the largest and most diverse federated HiFi datasets dedicated to rare disease research.
“HiFi whole genome sequencing delivers the accuracy and completeness required to confidently detect even the most challenging variants,” said Christian Henry, President and Chief Executive Officer of PacBio. “By partnering with DNAstack, we are extending the power of HiFi sequencing beyond individual institutions — enabling secure, federated analysis at global scale while maintaining local data control. This combination of technological precision and international collaboration strengthens variant interpretation and accelerates discoveries for patients with rare disease.”
By increasing statistical power for rare disease studies, the federated model enables insights that would be much more difficult, if not impossible, within siloed datasets — while preserving data sovereignty and meeting regional compliance requirements.
“Genome sequencing can help deliver answers to patients who need it most — but only if we can learn from global datasets while protecting participants’ privacy,” said Marc Fiume, CEO at DNAstack. “This partnership is proving the value of securely connecting leading hospitals and research centers around the world without moving sensitive data. By enabling collaboration at this scale, we’re helping clinicians reach answers faster, improve rare disease diagnosis, and build the foundation for learning health systems that benefit entire populations.”
“For rare disease genomic analysis, accuracy and completeness are essential,” said Eric Vilain, M.D., Ph.D., UC Irvine School of Medicine and a member of the HiFi Solves Global Consortium. “Taking advantage of the consortium’s federated model, we can securely filter variants and interpret findings in the context of a diverse global dataset while maintaining full control of patient data — ultimately delivering clearer answers to families faster and with greater confidence.”
HiFi sequencing plays a central role in the consortium’s impact on better resolving the genetic underpinnings of rare diseases. Its high accuracy and ability to resolve complex genomic regions, including paralogous genes and structural variants, provide clinical researchers with greater confidence in detecting disease-causing variants. When combined with federated data sharing, HiFi sequencing enables interpretation of rare variants within a broader global context — improving confidence in understanding the biology of rare diseases and, ultimately, accelerating time to answers for patients and families.
In November 2025, consortium members from the EMEA region published the first major study from the HiFi Solves initiative, “HiFi sequencing accurately identifies clinically relevant variants in paralogous genes,” demonstrating the value of federated HiFi whole genome sequencing at scale. In the study, HiFi sequencing detected 100% of known variants, reducing the need for multiple complementary technologies and simplifying workflows.
Launched in 2023, the HiFi Solves Global Consortium brings together leading clinical genomics research organizations focused on advancing the use of highly accurate HiFi sequencing in rare disease research. Since its inception, the consortium has nearly doubled in size, reflecting growing global demand for collaborative, privacy-preserving genomic research models.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About DNAstack
DNAstack builds the trust infrastructure for biomedical data collaboration. Its federated platform connects genomic and clinical data across institutions, enabling researchers and clinicians to learn together while data stays under local control. DNAstack powers national and international precision health initiatives and is a global leader in open standards through the Global Alliance for Genomics & Health (GA4GH).
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the collaboration with DNA Stack and the HiFi Solves Global Consortium to, among other things, expand the range of genomic insights of participating consortia members, enable secure analysis of genomic data while meeting regional compliance requirements, deliver answers to, among others, clinical researchers and families, and provide greater confidence both in detecting disease-causing variants and understanding the biology of rare diseases, and the commitment to connect more than 10,000 HiFi whole genome sequences, among other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in sequencing a large number of genomes and complying with evolving international privacy compliance requirements, the difficulty of generating discoveries in new areas of research or with respect to diseases that are rare; potential product performance and quality issues; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
FAQ**
How does the collaboration between DNAstack and Pacific Biosciences of California Inc. (PACB) enhance the accuracy and completeness of HiFi whole genome sequencing for rare disease research?
What measures are in place to ensure data sovereignty and compliance with regional privacy regulations in the initiative by Pacific Biosciences of California Inc. (PACB)?
With nearly institutions participating, how does Pacific Biosciences of California Inc. (PACB) plan to scale the HiFi Solves Global Consortium further to include more global datasets?
What challenges does Pacific Biosciences of California Inc. (PACB) foresee in the development and implementation of the federated model for HiFi sequencing data sharing across borders?
**MWN-AI FAQ is based on asking OpenAI questions about Pacific Biosciences of California Inc. (NASDAQ: PACB).
NASDAQ: PACB
PACB Trading
-2.89% G/L:
$1.345 Last:
3,158,107 Volume:
$1.35 Open:
